The European Medicines Agency (EMA) has announced a “rolling review” of data from two late stage COVID-19 vaccine candidates under development by AstraZeneca and Pfizer/BioNTech respectively. By reviewing data as it becomes available rather than reviewing a large quantity of data with the formal final application, the agency hopes to speed up evaluations of vaccines during the pandemic.